COMy 2023 - 9th World Congress on Controversies in Multiple Myeloma
May 11 - May 14, 2023 | ParisFrance
LARVOL is not affiliated with 9th World Congress on Controversies in Multiple Myeloma and all trademarks, logos, and brand names are property of their respective owners
Showing 14 titles linked to Trials
FORIMTAMIG, A GPRC5DXCD3 BISPECIFIC ANTIBODY, SHOWS PROMISING ACTIVITY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED RESULTS FROM A PHASE I STUDY INVESTIGATING IV AND SC DOSING
MODAKAFUSP ALFA: FINAL RESULTS FROM THE FIRST-IN-HUMAN PHASE 1/2 IINNOVATE-1 STUDY OF AN INNATE IMMUNITY ENHANCER IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
Efficacy Results, Ocular Adverse Events and Functional Impact in Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Belantamab Mafodotin plus Lenalidomide/ Dexamethasone in the Phase 1/2 BelaRd Study
SINGLE-AGENT BELANTAMAB MAFODOTIN (BELAMAF) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): FINAL ANALYSIS OF THE DREAMM-2 TRIAL
IN-CLASS TRANSITION FROM PARENTERAL BORTEZOMIB TO ORAL IXAZOMIB IN NEWLY DIAGNOSED MULTIPLE MYELOMA BY AGE AND FRAILTY STATUS: UPDATED SUBGROUP ANALYSES FROM THE FULLY ACCRUED US MM-6 COHORT
SAFETY AND EFFICACY OF LINVOSELTAMAB (REGN5458), A BCMAXCD3 BISPECIFIC ANTIBODY TREATMENT FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA: A PHASE 1/2 FIRST-IN-HUMAN STUDY
CILTACABTAGENE AUTOLEUCEL (CILTA-CEL), A BCMA-DIRECTED CAR-T CELL THERAPY, IN PATIENTS WITH MULTIPLE MYELOMA (MM) AND EARLY RELAPSE AFTER INITIAL THERAPY: CARTITUDE-2 COHORT B 18-MONTH FOLLOW-UP
MAJESTEC-1: CORRELATIVE ANALYSES OF TECLISTAMAB, A B-CELL MATURATION ANTIGEN X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
TALQUETAMAB, A G PROTEIN-COUPLED RECEPTOR FAMILY C GROUP 5 MEMBER D X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: PHASE 1/2 RESULTS FROM MONUMENTAL-1
TECLISTAMAB IN COMBINATION WITH SUBCUTANEOUS DARATUMUMAB AND LENALIDOMIDE IN PATIENTS WITH MULTIPLE MYELOMA: RESULTS FROM ONE COHORT OF MAJESTEC-2, A PHASE 1B, MULTICOHORT STUDY
DVRD FOLLOWED BY CILTACABTAGENE AUTOLEUCEL VERSUS DVRD FOLLOWED BY ASCT IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA WHO ARE TRANSPLANT ELIGIBLE: A RANDOMIZED PHASE 3 STUDY (EMAGINE/CARTITUDE-6)
HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA TREATED WITH TALQUETAMAB, A G PROTEIN-COUPLED RECEPTOR FAMILY C GROUP 5 MEMBER D X CD3 BISPECIFIC ANTIBODY: PATIENT-REPORTED OUTCOMES FROM MONUMENTAL-1
NO EVIDENCE OF B-CELL MATURATION ANTIGEN EXPRESSION LOSS OR SYSTEMIC IMMUNE IMPAIRMENT AFTER TREATMENT WITH THE BCMA-TARGETED ANTIBODY-DRUG CONJUGATE BELANTAMAB MAFODOTIN IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA
THE IINNOVATE CLINICAL DEVELOPMENT PROGRAM: RATIONALE AND DESIGN OF ONGOING PHASE 1/2 TRIALS OF MODAKAFUSP ALFA, AN INNATE IMMUNITY ENHANCER, IN PATIENTS WITH MULTIPLE MYELOMA